ClinicalTrials.gg
RecruitingNCT06616597Updated Feb 19, 2026

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

A Phase 2 interventional study of Abiraterone acetate and Dexamethasone in Prostate Cancer (Adenocarcinoma) and Metastatic Prostate Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.

Planned enrollment
46th of 98
58 · median 56
Started
2025
with 2 others
Phase 2
59 of 98
9 open now
Primary completion
2031-03
later than 28 of 28 live
Registered
94th of 98
by date
Lead sponsor
3 of 98
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 46th largest by planned enrollment, is one of 3 that started in 2025, is one of 59 in phase 2, reaches primary completion later than 28 of the 28 other live ones, and was the 94th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Abiraterone Acetate

Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, or all of them as a file.
02

Study summary

To determine if dexamethasone or dexamethasone plus metronidazole restore sensitivity to abiraterone for the treatment of metastatic prostate cancer.

Read the detailed description

To test whether giving dexamethasone with or without metronidazole in combination with abiraterone could help reverse resistance to abiraterone for patients with metastatic castration-resistant prostate cancer (mCRPC). Abiraterone and prednisone (AA/P) is a second-line therapy for mCRPC given when first-line androgen deprivation therapy fails. However, resistance to AA/P can develop. The investigators do not know exactly how cancer becomes resistant, but there is evidence that suggests it could be due to androgen production by the bacteria in your gut (gut microbiome). This study is focused on the gut microbiome as a source of androgen production that could cause AA/P resistance in mCRPC.

03

Conditions studied

  • Prostate Cancer (Adenocarcinoma)
  • Metastatic Prostate Cancer

Keywords

  • Abiraterone
  • microbiome
  • Dexamethasone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males aged 18 years of age and above.
  • Prostate adenocarcinoma
  • Absolute PSA ≥ 2.0 ng/mL at screening.
  • PSA (+/- radiographic) progression after having been on abiraterone and prednisone for at least 12 weeks.
  • Must be maintained on a GnRH analogue or have undergone orchiectomy.
  • Participants must have a ≥ 6 months
  • Ability to swallow study medication tablets
  • Willing to abstain from alcohol during and for 14 days after treatment with metronidazole
  • Willing and able to collect urine and stool samples per protocol

Exclusion criteria

Exclusion Criteria:

  • Active infection or other medical condition that would make dexamethasone use
  • Any chronic medical condition requiring a higher systemic dose of
  • Pathological finding consistent with small cell carcinoma of the prostate
  • Has imminent or established spinal cord compression based on clinical findings and/or MRI.
  • Chronic liver disease with class C cirrhosis (see calculator in protocol)
  • >3x or and ALT >5x ULN
  • Congenital prolonged syndrome or QTc > 500 msec (non-paced rhythm)
  • History of pituitary or adrenal dysfunction
  • Uncontrolled diabetes ( > 10%) or increasing doses of insulin within the past 4 weeks due to poorly controlled glucoses.
  • Administration of an therapeutic or invasive surgical procedure (not including surgical castration) within 30 days of Cycle 1 Day 1 or currently enrolled in an investigational drug study
  • Any other serious illness or medical condition that would, in the opinion of the investigator, make this protocol unreasonably hazardous, including, but not limited to:

    • Any uncontrolled major infection.
    • Crohn's disease or ulcerative colitis.
    • Known or suspected toxic megacolon and/or known small bowel ileus.
    • Known allergy to any of the compounds under investigation.
  • On antibacterial therapy within 30 days prior to administration of study treatment.
  • Any condition or situation which, in the opinion of the investigator, would put the subject at risk, or interfere with the subject's participation in this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    Arm 1: Abiraterone + Dexamethasone

    Abiraterone acetate plus dexamethasone

    Drug: Abiraterone acetate · Drug: Dexamethasone

  • Experimental
    Arm 2: Abiraterone + Dexamethasone + metronidazole

    Abiraterone acetate plus dexamethasone plus metronidazole

    Drug: Abiraterone acetate · Drug: Dexamethasone · Drug: Metronidazole

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with PSA30 response

    Number of participants with castration resistant prostate cancer who have a ≥ 30% decline in PSA from baseline until 24 weeks.

    Time frame: 24 weeks

Secondary outcomes

  1. Number of participants with PSA50 response

    Number of participants with castration resistant prostate cancer who have a ≥ 50% decline in PSA from baseline until 12 weeks.

    Time frame: 12 weeks

  2. PSA Progression Free Survival

    Number of participants with PSA progression according to PCWG3 (25% rise in PSA from nadir and increase of at least 2ng/mL)

    Time frame: 12 weeks

  3. Number of participants with progression

    progression is defined as: * Progression of soft tissue lesions according to RECIST 1.1 Criteria. * Progression of bone lesions detected with bone scan according to PCWG3 criteria. * Radiologically-confirmed spinal cord compression or pathological fracture due to malignant progression, or other clinical event deemed to be cancer-related, or death.

    Time frame: 24 weeks

  4. Number of grade 3-5 toxicities

    Toxicity is evaluated based on current CTCAE standard grading scales.

    Time frame: 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Mar 2031, 73 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 73 months is above that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2024
First posted
Sep 27, 2024
StartActual
Feb 13, 2025
Primary completionEst.
Mar 30, 2031
CompletionEst.
Mar 30, 2032
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06616597
Collaborators
United States Department of Defense, Prostate Cancer Foundation
Responsible party
Sponsor
First posted
Sep 27, 2024
Start date
Feb 13, 2025
Primary completion
Mar 30, 2031 (estimated)
Completion
Mar 30, 2032 (estimated)
Last update
Feb 19, 2026

Study contacts

Donna Bieg, RN
Contact
dieg2@jhmi.edu
410-502-7635
Catherine Handy Marshall, M.D.
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abiraterone Acetate

Start the discussion